Immunotherapy in the treatment of prostate cancer


MUDr. Jana Katolická, Ph.D.

Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno



Immunotherapy is not used in routine clinical practice in the treatment of prostate cancer. Traditional endpoints used to evaluate chemotherapy may not assess accurately the clinical benefit from immune therapies. The mechanism of action of most immune therapies is not directly cytotoxic. The higher clinical benefit was found in favorable subgroups with a lower tumor burden and a less immunosuppressive tumor microenvironment.


Key words

prostate cancer, imunotherapy



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...